Positive News SentimentPositive NewsNASDAQ:MLYS Mineralys Therapeutics (MLYS) Stock Forecast, Price & News $9.85 -0.25 (-2.48%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$9.70▼$10.2650-Day Range$9.85▼$15.1152-Week Range$9.70▼$21.98Volume88,547 shsAverage Volume200,407 shsMarket Capitalization$402.47 millionP/E RatioN/ADividend YieldN/APrice Target$36.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Mineralys Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside265.5% Upside$36.00 Price TargetShort InterestBearish9.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.61Based on 2 Articles This WeekInsider TradingSelling Shares$2.01 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.49) to ($2.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector569th out of 976 stocksPharmaceutical Preparations Industry262nd out of 450 stocks 3.5 Analyst's Opinion Consensus RatingMineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.00, Mineralys Therapeutics has a forecasted upside of 265.5% from its current price of $9.85.Amount of Analyst CoverageMineralys Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.93% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Mineralys Therapeutics has recently increased by 18.79%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMineralys Therapeutics does not currently pay a dividend.Dividend GrowthMineralys Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLYS. Previous Next 3.7 News and Social Media Coverage News SentimentMineralys Therapeutics has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Mineralys Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for MLYS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows1 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mineralys Therapeutics insiders have sold 2,409.62% more of their company's stock than they have bought. Specifically, they have bought $80,185.00 in company stock and sold $2,012,336.00 in company stock.Percentage Held by Institutions61.66% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.85) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Mineralys Therapeutics (NASDAQ:MLYS) StockMineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Read More MLYS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLYS Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Recommendation of "Buy" from BrokeragesSeptember 19, 2023 | finance.yahoo.comPraxis Bioresearch Expands its Board of Directors with Appointment of Adam LevySeptember 28, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 14, 2023 | finance.yahoo.comMineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne KarydasSeptember 11, 2023 | finance.yahoo.comMineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023September 11, 2023 | finance.yahoo.comMineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant HypertensionSeptember 10, 2023 | finance.yahoo.comMineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific SessionsSeptember 9, 2023 | finance.yahoo.comCEO Jon Congleton Buys 2,250 Shares of Mineralys Therapeutics Inc (MLYS)September 28, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 5, 2023 | finance.yahoo.comWall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High?September 5, 2023 | finance.yahoo.comMineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific SessionsAugust 29, 2023 | finance.yahoo.comMineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023August 22, 2023 | finance.yahoo.comMineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerAugust 8, 2023 | msn.comCredit Suisse Maintains Mineralys Therapeutics (MLYS) Outperform RecommendationAugust 8, 2023 | finance.yahoo.comMineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 31, 2023 | finance.yahoo.comMineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023July 28, 2023 | barrons.comMineralys Therapeutics Inc.July 27, 2023 | seekingalpha.comMineralys Therapeutics: Expanded Phase 2 Trials For Chronic Kidney DiseaseJuly 17, 2023 | finance.yahoo.comMineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)May 31, 2023 | finance.yahoo.comMineralys Therapeutics to Participate in the Jefferies Healthcare ConferenceMay 16, 2023 | msn.comCredit Suisse Reiterates Mineralys Therapeutics (MLYS) Outperform RecommendationMay 16, 2023 | finanznachrichten.deMineralys Therapeutics, Inc.: Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 16, 2023 | investing.comMineralys Therapeutics Inc (MLYS)May 15, 2023 | finance.yahoo.comMineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 15, 2023 | msn.comMarkets Today: Stocks Slide Despite Optimism About the Debt CeilingMay 10, 2023 | finance.yahoo.comWe Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business GrowthMay 2, 2023 | finance.yahoo.comMineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant HypertensionSee More Headlines Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Company Calendar Last Earnings8/07/2023Today9/28/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MLYS CUSIPN/A CIK1933414 Webwww.mineralystx.com Phone888-378-6240FaxN/AEmployees12Year FoundedN/APrice Target and Rating Average Stock Price Forecast$36.00 High Stock Price Forecast$45.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+265.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.88% Return on Assets-16.21% Debt Debt-to-Equity RatioN/A Current Ratio43.42 Quick Ratio43.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares40,860,000Free FloatN/AMarket Cap$402.47 million OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Jon Congleton (Age 60)CEO & Director Comp: $428.87kMr. Adam Scott Levy (Age 45)CFO, Chief Bus. Officer & Sec. Comp: $409.17kDr. David Rodman M.D. (Age 67)Chief Medical Officer Comp: $423.66kDr. Brian Taylor Slingsby M.D. (Age 46)M.P.H., Ph.D., Founder & Exec. Chairman Ms. Cindy BerejikianExec. VP of OperationsDr. Robert McKean Ph.D.Sr. VP of CMCMs. Danielle BradburySr. VP of Quality AssuranceMr. Jeffrey N. FellowsSr. VP of Regulatory AffairsMs. Jessica IbbitsonSr. VP of Clinical OperationsMr. Jose Breton CPA (Age 33)VP of Fin. & Controller More ExecutivesKey CompetitorsNurix TherapeuticsNASDAQ:NRIXOculisNASDAQ:OCSLiquidiaNASDAQ:LQDAProcaps GroupNASDAQ:PROCMarinus PharmaceuticalsNASDAQ:MRNSView All CompetitorsInsiders & InstitutionsBarclays PLCSold 9,758 shares on 9/21/2023Ownership: 0.007%Jon CongletonBought 2,250 shares on 9/6/2023Total: $27,180.00 ($12.08/share)Jon CongletonBought 2,250 shares on 8/17/2023Total: $27,225.00 ($12.10/share)Point72 Asset Management L.P.Bought 34,000 shares on 8/15/2023Ownership: 0.095%Goldman Sachs Group Inc.Sold 11,439 shares on 8/15/2023Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions MLYS Stock - Frequently Asked Questions Should I buy or sell Mineralys Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mineralys Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MLYS shares. View MLYS analyst ratings or view top-rated stocks. What is Mineralys Therapeutics' stock price forecast for 2023? 6 brokerages have issued twelve-month target prices for Mineralys Therapeutics' stock. Their MLYS share price forecasts range from $27.00 to $45.00. On average, they predict the company's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 265.5% from the stock's current price. View analysts price targets for MLYS or view top-rated stocks among Wall Street analysts. How have MLYS shares performed in 2023? Mineralys Therapeutics' stock was trading at $18.44 at the beginning of the year. Since then, MLYS stock has decreased by 46.6% and is now trading at $9.85. View the best growth stocks for 2023 here. When is Mineralys Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our MLYS earnings forecast. How were Mineralys Therapeutics' earnings last quarter? Mineralys Therapeutics, Inc. (NASDAQ:MLYS) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.52. When did Mineralys Therapeutics IPO? (MLYS) raised $180 million in an IPO on Friday, February 10th 2023. The company issued 12,000,000 shares at $14.00-$16.00 per share. What is Mineralys Therapeutics' stock symbol? Mineralys Therapeutics trades on the NASDAQ under the ticker symbol "MLYS." When did Mineralys Therapeutics' lock-up period expire? Mineralys Therapeutics' lock-up period expired on Wednesday, August 9th. Mineralys Therapeutics had issued 12,000,000 shares in its IPO on February 10th. The total size of the offering was $192,000,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period. Who are Mineralys Therapeutics' major shareholders? Mineralys Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (2.16%), Sectoral Asset Management Inc. (1.50%), Great Point Partners LLC (1.34%), Driehaus Capital Management LLC (1.22%), Sphera Funds Management LTD. (0.99%) and Geode Capital Management LLC (0.70%). Insiders that own company stock include Adam Scott Levy, David Malcom Rodman, Hbm Healthcare Investments (Ca, Jon Congleton and Ra Capital Management, LP. View institutional ownership trends. How do I buy shares of Mineralys Therapeutics? Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mineralys Therapeutics' stock price today? One share of MLYS stock can currently be purchased for approximately $9.85. How much money does Mineralys Therapeutics make? Mineralys Therapeutics (NASDAQ:MLYS) has a market capitalization of $402.47 million. How can I contact Mineralys Therapeutics? The official website for the company is www.mineralystx.com. The company can be reached via phone at 888-378-6240 or via email at investorrelations@mineralystx.com. This page (NASDAQ:MLYS) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.